• Why the CSN2 Locus Raises Rabbit Pharming Yield

  2026-11-04

  A targeted rabbit line linked recombinant reporter expression to the endogenous CSN2 milk-protein locus, producing 15–20 g/L in milk from homozygous animals. The finding supports a promoter-and-locus mechanism, while leaving protein quality, scalability, and generalizability unresolved.

• What High-Yield Rabbit Pharming Evidence Shows

  2026-11-04

  A targeted rabbit line produced substantially higher reported milk levels of a recombinant reporter than the heterogeneous yields historically associated with conventional transgenesis. The result supports a strong proof of concept for locus-directed expression, but it does not yet establish general performance across therapeutic proteins, rabbit lines, or manufacturing contexts.

• Can Endogenous Promoters Raise Pharming Yield?

  2026-11-03

  A 2025 rabbit study linked a recombinant reporter gene to the endogenous CSN2 milk-protein locus and reported 15–20 g/L in milk from two homozygous animals. The result supports locus-aware expression as a promising proof of concept, but it does not yet establish general performance across therapeutic proteins, rabbit lines, or production settings.

• Can Targeted Rabbit Lines Raise Pharming Yield?

  2026-11-03

  A targeted rabbit line using the endogenous CSN2 regulatory context produced substantially more reporter protein in milk than historical pharming benchmarks. The result supports locus-directed expression as a promising strategy, but it does not yet establish equivalent performance for therapeutic proteins or a complete production platform.

• How CSN2 Targeting Raised Rabbit Milk Yield

  2026-11-02

  A 2025 study reported that placing a tdTomato reporter at the rabbit CSN2 locus produced 15–20 g/L in milk from two homozygous animals. The result supports a locus-targeted, endogenous-promoter strategy, while leaving important questions about therapeutic proteins, reproducibility, animal performance, and product quality unanswered.

• Why the CSN2 Locus Raised Rabbit Pharming Yields

  2026-11-02

  A literature-focused analysis of a 2025 study showing that targeted placement of a reporter transgene at the rabbit CSN2 locus produced substantially higher milk concentrations than historical conventional transgenic examples. The findings support a strong locus-and-promoter rationale, while leaving important questions about protein quality, animal-to-animal reproducibility, therapeutic-protein generalizability, and direct comparability unresolved.

• Reading Golgi Fragmentation in Cancer Cells

  2026-11-01

  A Golgi fluorescent probe helped localize and interpret organelle changes in a study of a tumor-targeted heptamethine cyanine dye. The evidence supports Golgi disruption as a mechanistic correlate of progesterone-receptor suppression, but does not yet establish that fragmentation is the initiating cause or that the imaging probe contributes to the antitumor effect.

• What the Rabbit Pharming Comparison Really Shows

  2026-10-31

  A targeted rabbit line produced substantially higher reporter-protein concentrations than historical conventional lines, but the evidence remains a proof of concept rather than a controlled demonstration that one design feature caused the improvement.

• Why CSN2 Targeting Raised Rabbit Milk Yields

  2026-10-30

  A 2025 study used targeted insertion at the rabbit CSN2 locus to place a reporter gene under the control of an endogenous milk-protein promoter. The resulting homozygous animals produced 15–20 g/L of reporter protein in milk, but the evidence remains a proof of concept rather than a direct demonstration of therapeutic-protein manufacturing performance.

• How CSN2 Targeting Raises Rabbit Milk Yield

  2026-10-30

  A 2025 study links targeted insertion at the endogenous CSN2 locus with markedly higher reporter-protein concentrations in rabbit milk. The result supports a promoter-and-locus mechanism, while the small number of animals and use of tdTomato limit how broadly the finding can be generalized.

• Why CSN2 Knock-In Raises Rabbit Milk Protein Yield

  2026-10-29

  A 2025 study linked targeted insertion at the rabbit CSN2 locus with unusually high milk concentrations of a reporter protein. The evidence supports endogenous promoter choice and controlled genomic context as plausible drivers, but the study cannot isolate those effects from allele dosage, protein identity, or other features of the line-generation strategy.

• What High-Yield Rabbit Pharming Data Really Show

  2026-10-29

  A targeted rabbit line produced substantially higher milk concentrations of a fluorescent reporter than the historical ranges summarized for conventional lines. The result supports the importance of locus and promoter choice, but it does not yet establish equivalent performance for therapeutic proteins or prove that the editing platform alone caused the increase.

• How a Light-Chain Peptide Informs Antibody Study

  2026-10-28

  An Immunoglobulin light chain variable region fragment can clarify sequence-level and local interaction questions, but it cannot reproduce the folded, paired antigen-binding site of an intact antibody. Its strongest interpretation is therefore molecular and structural, not a direct measure of complete antibody specificity.

• How Alpha-Endorphin Signals Become Readouts

  2026-10-27

  Alpha-Endorphin is best interpreted as a POMC-derived endogenous opioid peptide whose molecular identity, receptor interaction, cellular response, neural-circuit activity and behavior represent different levels of evidence. This article explains how those levels connect—and why a signal associated with opioid receptor signaling should not automatically be read as proof of analgesia or reward.

• How Bupropion Links Reuptake to Cell Stress

  2026-10-27

  Bupropion hydrochloride is described as affecting norepinephrine and dopamine transporter activity while also producing stress-related cellular findings in SH-SY5Y neuroblastoma cells. The key interpretive question is how these measurements relate: transporter inhibition, altered dopamine biology, ER stress, and caspase 3-dependent cell death represent different levels of evidence and should not be treated as one directly demonstrated clinical pathway.

8674 records 1/579 page Next 12345 下5页 Last page